隆培促生长素(Lonapegsomatropin-tcgd) - 药物靶点：GR_在研适应症：生长激素缺乏症，软骨发育不全，特纳综合症_专利_临床

概要

基本信息

药物类型

激素

别名

Lonapegsomatropin、TransCon、TransCon growth hormone

+ [9]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病+ [4]

在研适应症

生长激素缺乏症软骨发育不全特纳综合症

非在研适应症-

原研机构

Ascendis Pharma A/S

在研机构

维昇药业（上海）有限公司Ascendis Pharma Endocrinology Division A/S

Ascendis Pharma A/S

+ [2]

非在研机构

VISEN Pharmaceuticals

权益机构

Teijin Pharma Ltd.

维昇药业（上海）有限公司Specialised Therapeutics Asia Pte Ltd.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2021-08-25),

生长激素缺乏症

最高研发阶段(中国)申请上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 26401985

来源: *****

关联

16

项与隆培促生长素相关的临床试验

CTIS2023-508341-40-00

/ Not yet recruiting临床2期

COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia - ASND0042

开始日期2024-07-26

申办/合作机构

Ascendis Pharma Growth Disorders A/S

NCT06433557

/ Active, not recruiting临床2期

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

开始日期2024-07-26

申办/合作机构

Ascendis Pharma Growth Disorders A/S

NCT05775523

/ RecruitingN/A

A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

开始日期2023-03-20

申办/合作机构

Ascendis Pharma Endocrinology Division A/S

100 项与隆培促生长素相关的临床结果

登录后查看更多信息

100 项与隆培促生长素相关的转化医学

登录后查看更多信息

100 项与隆培促生长素相关的专利（医药）

登录后查看更多信息

739

项与隆培促生长素相关的文献（医药）

2025-05-04·Expert Review of Endocrinology & Metabolism

Long-acting growth hormone in the treatment of children with growth hormone deficiency

Review

作者: Iughetti, Lorenzo ; Predieri, Barbara ; Lucaccioni, Laura ; Insalaco, Anna

INTRODUCTION:

The introduction of long-acting formulations in recent years is changing the landscape of growth hormone (GH) therapy. Daily recombinant human GH (rhGH) has been the treatment of choice for children and adults with GH deficiency (GHD), since its approval in 1985. However, decreasing adherence to treatment over time has been identified as a cause of the decline in rhGH efficacy, leading to significant efforts to develop long-acting rhGH (LAGH) formulations.

AREAS COVERED:

A comprehensive analysis of the literature was conducted to evaluate their mechanism of action, pharmacokinetics, pharmacodynamics, efficacy, safety profile, and administration route. The review focuses on the LAGH approved from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of pediatric growth hormone deficiency (PGHD): Lonapegsomatropin, Somatrogon and Somapacitan. We aim to facilitate evidence-based clinical decisions by analyzing the available data on the three LAGH formulations.

EXPERT OPINION:

Even if current evidence suggests a non-inferiority of all the three LAGH formulations when compared to daily rhGH, long-term concerns persist regarding the non-physiological GH profile associated with LAGH, characterized by weekly instead of daily peaks. Further research and real-life studies are required to better define the long-term efficacy of these formulations.

2025-04-30·Annals of Pediatric Endocrinology & Metabolism

Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency

Article

作者: Faleschini, Elena ; Tornese, Gianluca ; Rodaro, Chiara ; Tamaro, Gianluca

Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy. Traditional rhGH treatments, although effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life. LAGHs have demonstrated non-inferiority to daily rhGHs in phase 3 clinical trials, showing similar efficacy in terms of growth velocity and safety profiles. Despite these advantages, concerns remain regarding the altered pharmacodynamics of LAGHs such as the lack of pulsatile secretion and potential for antibody formation. Although the overall safety of LAGHs has been confirmed, side effects, such as lipoatrophy at the injection site, may occur, especially with PEGylated formulations. Guidelines for prescribing LAGHs are currently evolving. LAGHs are not yet approved for other conditions traditionally treated with rhGHs, such as Turner or Noonan syndrome. Pediatric endocrinologists should carefully consider which patient groups would benefit most from this therapy, particularly individuals at risk of poor adherence to daily injections such as patients undergoing multidrug therapy, patients with needle phobia or behavioral disorders, very young children, adolescents, patients with separated parents, families that travel frequently, or children involved in activities such as scouting. LAGHs present an opportunity to enhance therapeutic outcomes and adherence, but careful patient selection remains critical to maximize their potential benefits.

2025-03-26·JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

Clinical outcomes of switching to lonapegsomatropin from somatropin for treatment of pediatric growth hormone deficiency

Article

作者: Coyne, Emma ; Muthuvel, Gajanthan ; Gutmark-Little, Iris

Abstract:

Objectives:

This study aimed to assess differences in insulin-like growth factor 1 (IGF-1) levels following the transition from somatropin to lonapegsomatropin in patients with pediatric growth hormone deficiency (GHD). Secondary objectives included the evaluation of dose titrations based on IGF-1 levels, changes in annualized height velocity (AHV) and body mass index (BMI), and assessing reported adverse effects associated with lonapegsomatropin therapy.

Methods:

A single-center, retrospective review was conducted including patients diagnosed with pediatric GHD initially treated with somatropin who transitioned to lonapegsomatropin between January 1, 2022, and December 31, 2023.

Results:

Fourteen patients (median age: 9 years) were included. The median somatropin dose was 0.18 mg/kg/week (range, 0.09 to 0.29) at the time of transition and patients were initiated on a median lonapegsomatropin dose of 0.23 mg/kg/week (range, 0.15 to 0.26). This resulted in an IGF-1 increase of 2.3 SDS post-switch. Dose adjustments were made based on IGF-1 levels. Five patients required immediate dose reductions; four of these required further adjustments due to persistent elevation. There were no serious adverse effects reported.

Conclusions:

Lonapegsomatropin may be a favorable option to reduce injection burden for those with pediatric GHD, though the manufacturer’s recommended starting dose of 0.24 mg/kg/week may require individualization. Careful monitoring and dose adjustment based on IGF-1 levels are necessary to maintain safety and efficacy.

170

项与隆培促生长素相关的新闻（医药）

2025-05-13

·FiercePharma

Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders

The FDA first approved Sogroya in August 2020 as a once-weekly treatment for adult growth hormone deficiency. The drug’s label was expanded to include children in April 2023. With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in the realm of rare disease.Over the weekend, Novo unveiled data from the phase 3 Real8 study, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor, Norditropin, in a trio of growth disorders in kids.At the basket study’s 52-week mark, Sogroya—first approved in 2020—proved noninferior to Norditropin at improving yearly growth rate in prepubescent children with idiopathic short stature (ISS).Meanwhile, Sogroya demonstrated superiority over Novo’s daily growth hormone in children with Noonan syndrome (NS) and in children born small for gestational age (SGA) when compared to a lower Norditropin dose.When pitted against a higher dose of its growth hormone predecessor in SGA, Sogroya’s efficacy was noninferior, Novo explained in its Monday release.Sogroya was well tolerated in the study, and no new safety flags cropped up that diverged from Norditropin’s long-established profile, the company added.Sogroya’s performance in Real8 allowed the first three sub-studies to meet their primary endpoints. Leveraging data from Real8 and Real9, Novo said it has already filed for approval of Sogroya in SGA, NS and ISS with regulators in the U.S. and Europe.Novo’s Real8 program is also testing Sograya’s mettle in Turner syndrome, though those data won’t arrive until “later this year,” the company said. The FDA first approved Sogroya in August 2020 as a once-weekly treatment for adult growth hormone deficiency. The drug’s label was expanded to include children in April 2023.Sogroya is meant to succeed Novo’s once-a-day growth hormone Norditropin, which has now been on the market for decades. Eli Lilly, Merck & Co. and Pfizer all sell their own daily growth disorder drugs, while newer meds like Ascendis’ Skytrofa and Pfizer’s Ngenla are challenging Sogroya directly on the weekly-dosing front.Novo lumps sales of Norditropin and Sogroya together into its rare endocrine disorders category, which grew sales 31% in 2024 to roughly 5 billion Danish kroner ($745 million).Analytics firm GlobalData has forecast Sogroya will hit $294 million in 2030 sales and expects Norditropin to reach $960 million in sales that same year. The Sogroya results have likely bolstered Novo’s confidence in rare disease, where the company has been playing a “long endgame” since the late 2010s, Ludovic Helfgott, the company’s executive vice president of rare disease, said in a March interview with Fierce Pharma.Aside from drugs for growth disorders like Norditropin and Sogroya, Novo’s rare disease pedigree includes treatments for blood disorders like Esperoct, NovoEight or the recently approved daily hemophilia injection Alhemo, Helfgott explained.Novo plans to stick to those two major disease areas—growth and blood disorders—as it presses forward in the field.“It’s our core, and we will continue to develop this both internally and externally,” Helfgott said.

临床3期上市批准临床结果

2025-05-13

·药时空

疗效持续4年！维昇药业特立帕肽前药甲状腺功能减退2期临床长期随访结果

5月12日（当地时间），Ascendis Pharma（中国子公司：维昇药业）宣布Yorvipath（Palopegteriparatide，中文名：帕罗培特立帕肽，研发名称：TransCon PTH）成人甲状腺功能减退2期临床研究（PaTH Forward）214周最新研究结果证实其长期持久的疗效。PaTH Forward研究（NCT04009291)为在4周随机、双盲、安慰剂对照研究后进入为期266周的开放标签扩展研究。214周时，59例患者中的56例（95%)仍在接受治疗。214周研究结果如下：98%患者白蛋白校正血清钙水平继续维持正常范围内,93%患者摆脱现有疗法（定义：钙＜600mg/天&无需Vd）；骨转换标志物CTx（胶原C端肽）和P1NP（总I型胶原氨基端延长肽）从基线正常低端增加，26周到达峰值后下降并在214周维持稳定在基线水平之上；骨骼动力学改善：BMD维持在年龄和性别匹配正常范围内；67.8%患者eGFR（肾小球滤过率）具有临床意义增加（≥5ml/min/1.73m^2),eGFR从第4周明显变化。安全性方面，耐受性良好，无新的安全性信号，TEAE多为轻或中度，无重度或药物相关停药。Yorvipath（Palopegteriparatide，中文名：帕罗培特立帕肽，研发名称：TransCon PTH）为特立帕肽（PTH 1-34）前药，每天一次即可在24h内持续释放PTH。2018年，Ascendis授予Visen（维昇药业）大中华区开发和商业化TransCon hGH、TransCon PTH和TransCon CNP的独家权利。Yorvipath在2023年6月获得欧洲药品管理局批准上市，作为成人慢性甲状腺功能减退患者的替代性疗法。商品名与FDA批准的相同，规格有三种：168μg/0.56ml、294μg/0.98ml、420μg/1.4ml，剂型均为预充笔注射液。FDA的审批过程颇为曲折，2022年8月ascendis Pharma递交NDA申请获FDA受理并获得优先审评，2023年5月FDA下发完整回复函（CRL）提出药械组合的剂量传输控制策略问题，同年12月ascendis Pharma重新递交NDA申请并获FDA受理，而在2024年5月FDA又因审查过程中重大变更导致审评时限延长3月至2024年8月14日。2024年8月，FDA最终批准上市，用于甲状腺功能减退患者的替代性疗法。维昇药业2024年8月公布帕罗培特立帕肽用于治疗成人慢性甲状旁腺功能减退症的中国3期临床试验（PaTHway China），26周随机、双盲、安慰剂对照部分的数据：与安慰剂组相比，帕罗培特立帕肽组达到了主要复合终点的患者比例显著更高。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

优先审批上市批准临床2期突破性疗法临床3期

2025-05-05

·GlobeNewswire-Health Care

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen. Four oral presentations will feature Ascendis clinical trial results, including 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism; Week 52 growth and bone morphometry data from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia; and efficacy and safety data from the Phase 3 foresiGHt Trial of TransCon hGH (lonapegsomatropin) in adults with growth hormone deficiency. “As new treatments and clinical practices transform the outlook for rare endocrine diseases, we are pleased to partner with trial investigators and leading experts to share new data highlighting clinical benefits of our novel therapies with attendees of ESPE & ESE 2025,” said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma. The full range of Ascendis Pharma events and updates at ESPE & ESE 2025 include the following: Hypoparathyroidism Sunday, May 1109:55 - 10:25 CEST Congress TheaterFoyer F5Product TheaterRestoring Physiological Levels of PTH in Chronic HypoparathyroidismClick here to see the full session outline.Sunday, May 1116:55-17-55 CEST& Monday, May 1217:15-17:45 CESTPoster HallPoster P238Estimating the Risk of Chronic Kidney Disease Progression in Chronic Hypoparathyroidism: A Restrospective Matched Cohort Study, Using Real-World Data from England Monday, May 1213:00 - 14:30 CESTRoom D5SymposiumBeyond Conventional Care: Redefining Treatment Success in Chronic HypoparathyroidismClick here to see the full session outline.Monday, May 1215:55-16:05 CESTRoom C2Oral PresentationLong-Term Efficacy & Safety of Palopegteriparatide Treatment in Adults with Chronic Hypoparathyroidism: 4-Year Results from the Phase 2 PaTH Forward TrialPresented by Dr. Andrea PalermoAchondroplasiaSunday, May 1115:55-17:25 CESTRoom C2SymposiumAssessing HRQoL in Achondroplasia Across the Life CourseClick here to see the full session outline.Monday, May 1215:15-15:25 CESTRoom C2Oral PresentationEffects of Navepegritide on Bone Morphometry in Children with Achondroplasia: 52-Week Results from the ApproaCH Clinical TrialPresented by Dr. Leanne WardTuesday, May 1315:05-15:15 CESTRoom D2Oral PresentationEffects of Navepegritide on Growth in Children with Achondroplasia: 52-Week Results from the ApproaCH Clinical TrialPresented by Dr. Hanne HoveGrowth Hormone DeficiencyTuesday, May 1314:45-14:55 CESTRoom D2Oral PresentationResults of the foresiGH Trial Support the Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults with Growth Hormone Deficiency (GHD)Presented by Dr. Aleksandra Gilis-Januszewska More information about the events and presentations listed here is available to registered attendees of the Joint ESPE & ESE 2025 congress. About HypoparathyroidismHypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes. About AchondroplasiaAchondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal deformities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can have detrimental effects on quality of life, physical functioning, and psychosocial function. Individuals with achondroplasia often require multiple surgeries and procedures to alleviate the condition’s many complications. About Adult Growth Hormone DeficiencyGrowth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual’s body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the clinical benefits of Ascendis’ novel therapies, (ii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (iii) Ascendis’ application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © May 2025 Ascendis Pharma A/S. Investor Contacts: Scott Smith Ascendis Pharma ir@ascendispharma.com Media Contact:Melinda BakerAscendis Pharmamedia@ascendispharma.com Patti BankICR Healthcare+1 (415) 513-1284patti.bank@icrhealthcare.com

临床2期临床结果

100 项与隆培促生长素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	隆培促生长素	-	DB16220

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
生长激素缺乏症	美国	Ascendis Pharma Endocrinology Division A/S	2021-08-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
内分泌系统疾病	临床3期	中国	维昇药业（上海）有限公司	2019-12-30
内分泌系统疾病	临床3期	中国	Ascendis Pharma A/S	2019-12-30
垂体疾病	临床3期	中国	Ascendis Pharma A/S	2019-12-30
垂体疾病	临床3期	中国	维昇药业（上海）有限公司	2019-12-30
软骨发育不全	临床2期	丹麦	Ascendis Pharma Growth Disorders A/S	2024-07-26
软骨发育不全	临床2期	爱尔兰	Ascendis Pharma Growth Disorders A/S	2024-07-26
软骨发育不全	临床2期	英国	Ascendis Pharma Growth Disorders A/S	2024-07-26
特纳综合症	临床2期	美国	Ascendis Pharma A/S	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04615273 (foresiGHt, CTgov)	临床3期	生长激素缺乏症	264	Lonapegsomatropin (Lonapegsomatropin)	範窪窪齋製鹽鬱網觸衊(鏇衊網築獵憲廠糧遞壓) = 觸築簾憲餘構淵壓網繭繭觸糧遞餘願鑰願淵鬱 (顧壓範餘願蓋簾鹽願壓, 餘憲範製齋願鏇蓋範鏇 ~ 製淵選艱齋夢網憲繭構) 更多	-	2025-01-15
				Placebo (Placebo)	範窪窪齋製鹽鬱網觸衊(鏇衊網築獵憲廠糧遞壓) = 積窪鬱鏇簾醖鏇範簾鹹繭觸糧遞餘願鑰願淵鬱 (顧壓範餘願蓋簾鹽願壓, 顧糧觸積廠選築醖遞醖 ~ 壓窪衊窪製願觸夢製窪) 更多
NCT03344458 (enliGHten, CTgov)	临床3期	生长激素缺乏症	298	Lonapegsomatropin	鏇淵醖繭簾鬱顧窪蓋獵 = 製鹹淵膚餘繭膚鑰餘齋範鬱衊憲築積網醖窪簾 (齋壓膚獵製鏇壓憲觸襯, 願顧夢鹹繭簾構獵鏇繭 ~ 餘選廠憲蓋鑰夢齋遞願) 更多	-	2024-05-08
NCT04615273 (foresiGHt, Biospace) 人工标引	临床3期	生长激素缺乏症	259	TransCon hGH	積衊遞築夢範獵鑰網遞(夢廠淵蓋遞鹹獵鹽顧餘) = 築遞築壓製積糧製範積鏇壓蓋齋淵積構襯艱選 (窪醖鹽餘鬱艱窪餘醖艱 ) 更多	积极	2023-12-19
				Placebo	積衊遞築夢範獵鑰網遞(夢廠淵蓋遞鹹獵鹽顧餘) = 夢窪鹹窪範鏇網鹽醖繭鏇壓蓋齋淵積構襯艱選 (窪醖鹽餘鬱艱窪餘醖艱 ) 更多
NCT03344458 (enliGHten, GlobeNewswire) 人工标引	N/A	生长激素缺乏症	81	TransCon hGH	觸構願糧簾構積願齋獵(範膚糧壓淵夢顧願鏇廠) = The most commonly reported adverse events over the course of the trial were categorized as infections, injury, and respiratory/thoracic/medical disorders. The majority of adverse events were mild in severity and unrelated to treatment. No adverse events led to discontinuation of the study treatment. 窪醖廠醖蓋獵繭鬱餘積 (襯築繭範鏇壓餘壓選鹽 )	积极	2023-09-23
				TransCon hGH (at the beginning of the open-label extension trial)
NCT04326374 (PRNewswire) 人工标引	临床3期	生长激素缺乏症	150	human growth hormone (Longpei growth promoting hormone group)	餘蓋鹽遞觸壓顧壓夢膚(觸網鑰衊願觸觸遞壓襯) = 膚遞壓繭夢選鑰壓窪積鑰鏇構餘衊膚鬱顧艱簾 (顧膚鑰鹽獵鹽齋鬱範構 )	积极	2022-11-17
				human growth hormone (growth hormone daily preparation group)	餘蓋鹽遞觸壓顧壓夢膚(觸網鑰衊願觸觸遞壓襯) = 選願簾顧願夢鹹選膚淵鑰鏇構餘衊膚鬱顧艱簾 (顧膚鑰鹽獵鹽齋鬱範構 )
enliGHten Trial (ENDO2022)	临床3期	生长激素缺乏症	298	Lonapegsomatropin via vial/syringe	廠夢淵積觸積糧願艱鑰(膚簾簾襯鏇鏇窪齋鏇觸) = With continued lonapegsomatropin treatment, the AE profile remained consistent with what was observed in the parent trials, with no new safety signals 醖齋鏇範醖衊願鹹觸範 (齋獵範顧衊壓鹹鹹顧構 )	积极	2022-11-01
NCT04326374 (PRNewswire) 人工标引	临床3期	生长激素缺乏症	150	lonapegsomatropin	構襯鑰鹹醖範憲網鑰積(夢願襯繭積膚鹹構窪範): P-Value = 0.0010	优效	2022-05-23
				daily growth hormone
NCT03305016 (CTgov)	临床3期	生长激素缺乏症	146	Lonapegsomatropin	衊夢夢蓋築積蓋夢糧鑰 = 淵鹽糧淵淵遞鹹顧選鹽艱積積鏇壓構鏇獵餘廠 (蓋獵齋壓積壓積鑰觸獵, 願窪淵壓蓋願蓋積獵廠 ~ 鹹製獵繭願廠廠糧鹽鏇) 更多	-	2022-01-04
heiGHt Trial (ENDO2020)	临床3期	生长激素缺乏症维持	159	TransCon hGH	蓋衊淵窪憲膚獵鏇鏇製(選廠壓壓鬱衊築顧積選) = 繭憲廠網顧遞糧膚壓選齋積願壓齋鬱鏇簾鏇淵 (簾鹹積衊淵製遞鏇鏇獵 ) 更多	积极	2020-05-08
				Genotropin	蓋衊淵窪憲膚獵鏇鏇製(選廠壓壓鬱衊築顧積選) = 鑰鬱簾艱糧範餘構廠夢齋積願壓齋鬱鏇簾鏇淵 (簾鹹積衊淵製遞鏇鏇獵 )
NCT01947907 (Pubmed \| J Clin Endocrinol Metab) 人工标引	临床2期	生长激素缺乏症	53	TransCon GH	觸鬱夢網築艱積遞選窪(遞積鏇鬱遞製淵醖鏇製) = 壓鹽遞襯遞壓願壓齋繭窪獵夢製憲鹹願窪觸膚 (膚壓鬱鑰膚淵窪鏇廠簾 )	积极	2017-05-01
				Genotropin	觸鬱夢網築艱積遞選窪(遞積鏇鬱遞製淵醖鏇製) = 鏇艱鑰艱膚鹽鏇齋鏇襯窪獵夢製憲鹹願窪觸膚 (膚壓鬱鑰膚淵窪鏇廠簾 )